- Home
- INFY vs REGN Comparison
INFY vs REGN Comparison
Compare INFY & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFY
- REGN
- Stock Information
- Founded
- INFY 1981
- REGN 1988
- Country
- INFY India
- REGN United States
- Employees
- INFY N/A
- REGN N/A
- Industry
- INFY EDP Services
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- INFY Technology
- REGN Health Care
- Exchange
- INFY Nasdaq
- REGN Nasdaq
- Market Cap
- INFY 96.0B
- REGN 110.0B
- IPO Year
- INFY 1999
- REGN 1991
- Fundamental
- Price
- INFY $22.83
- REGN $711.35
- Analyst Decision
- INFY Hold
- REGN Buy
- Analyst Count
- INFY 8
- REGN 24
- Target Price
- INFY $20.22
- REGN $1,054.00
- AVG Volume (30 Days)
- INFY 6.7M
- REGN 851.5K
- Earning Date
- INFY 01-09-2025
- REGN 01-31-2025
- Dividend Yield
- INFY 2.49%
- REGN N/A
- EPS Growth
- INFY 5.91
- REGN 15.31
- EPS
- INFY 0.77
- REGN 40.43
- Revenue
- INFY $18,836,000,000.00
- REGN $13,847,100,000.00
- Revenue This Year
- INFY $3.41
- REGN $10.15
- Revenue Next Year
- INFY $9.23
- REGN $3.82
- P/E Ratio
- INFY $29.30
- REGN $17.52
- Revenue Growth
- INFY 1.56
- REGN 5.72
- 52 Week Low
- INFY $16.04
- REGN $693.00
- 52 Week High
- INFY $23.63
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- INFY 47.44
- REGN 28.91
- Support Level
- INFY $22.62
- REGN $693.00
- Resistance Level
- INFY $23.62
- REGN $745.00
- Average True Range (ATR)
- INFY 0.36
- REGN 20.84
- MACD
- INFY -0.04
- REGN 0.44
- Stochastic Oscillator
- INFY 29.06
- REGN 13.82
About INFY Infosys Limited
Infosys is a leading global IT services provider, with nearly 250,000 employees. Based in Bangalore, the Indian IT services firm leverages its offshore outsourcing model to derive 60% of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services and cloud infrastructure services, and business process outsourcing as a service (BPaaS).
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).